118 related articles for article (PubMed ID: 19328570)
1. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
Petit SF; Aerts HJ; van Loon JG; Offermann C; Houben R; Winkens B; Ollers MC; Lambin P; De Ruysscher D; Dekker AL
Radiother Oncol; 2009 Jun; 91(3):393-8. PubMed ID: 19328570
[TBL] [Abstract][Full Text] [Related]
2. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
3. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
4. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
5. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice.
Schütze C; Bergmann R; Yaromina A; Hessel F; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
Radiother Oncol; 2007 Jun; 83(3):311-5. PubMed ID: 17502117
[TBL] [Abstract][Full Text] [Related]
6. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
[TBL] [Abstract][Full Text] [Related]
7. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
Abramyuk A; Tokalov S; Zöphel K; Koch A; Szluha Lazanyi K; Gillham C; Herrmann T; Abolmaali N
Radiother Oncol; 2009 Jun; 91(3):399-404. PubMed ID: 19168248
[TBL] [Abstract][Full Text] [Related]
8. [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.
Petit SF; van Elmpt WJ; Oberije CJ; Vegt E; Dingemans AM; Lambin P; Dekker AL; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):698-705. PubMed ID: 20884128
[TBL] [Abstract][Full Text] [Related]
9. Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.
Bosmans G; van Baardwijk A; Dekker A; Ollers M; Wanders S; Boersma L; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):139-44. PubMed ID: 17996384
[TBL] [Abstract][Full Text] [Related]
10. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
11. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.
De Ruysscher D; Houben A; Aerts HJ; Dehing C; Wanders R; Ollers M; Dingemans AM; Hochstenbag M; Boersma L; Borger J; Dekker A; Lambin P
Radiother Oncol; 2009 Jun; 91(3):415-20. PubMed ID: 19195730
[TBL] [Abstract][Full Text] [Related]
12. Tumour control probability of stage III inoperable non-small cell lung tumours after sequential chemo-radiotherapy.
El Sharouni SY; Kal HB; Battermann JJ
Anticancer Res; 2005; 25(6C):4655-61. PubMed ID: 16334157
[TBL] [Abstract][Full Text] [Related]
13. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Aerts HJ; Bussink J; Oyen WJ; van Elmpt W; Folgering AM; Emans D; Velders M; Lambin P; De Ruysscher D
Lung Cancer; 2012 Jan; 75(1):73-6. PubMed ID: 21782272
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome.
van der Voort van Zyp NC; Prévost JB; Hoogeman MS; Praag J; van der Holt B; Levendag PC; van Klaveren RJ; Pattynama P; Nuyttens JJ
Radiother Oncol; 2009 Jun; 91(3):296-300. PubMed ID: 19297048
[TBL] [Abstract][Full Text] [Related]
15. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan.
Zhao L; Wang L; Ji W; Wang X; Zhu X; Hayman JA; Kalemkerian GP; Yang W; Brenner D; Lawrence TS; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1385-90. PubMed ID: 19231104
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
17. Prediction of residual metabolic activity after treatment in NSCLC patients.
Velazquez ER; Aerts HJ; Oberije C; De Ruysscher D; Lambin P
Acta Oncol; 2010 Oct; 49(7):1033-9. PubMed ID: 20831492
[TBL] [Abstract][Full Text] [Related]
18. New approaches to radiotherapy as definitive treatment for inoperable lung cancer.
Berman AT; Rengan R
Semin Thorac Cardiovasc Surg; 2008; 20(3):188-97. PubMed ID: 19038727
[TBL] [Abstract][Full Text] [Related]
19. Evolution of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Apr; 56(4):516-524. PubMed ID: 28358668
[TBL] [Abstract][Full Text] [Related]
20. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
